Postoperative anlotinib plus radiotherapy in patients with newly diagnosed, unmethylated O 6 ‐methylguanine–DNA methyltransferase glioblastoma: A single‐arm, phase 2 study
Abstract
Background: Patients with unmethylated O 6 ‐methylguanine–DNA methyltransferase ( MGMT ) glioblastoma derive minimal benefit from the standard temozolomide chemoradiotherapy, leaving an urgent need for more effective therapies. The objective of this phase 2 study was to evaluate the efficacy of anlotinib plus radiotherapy in this disease. Methods: In this single‐arm, phase 2 study, patients with newly diagnosed, unmethylated MGMT glioblastoma were recruited after surgical resection. Patients received standard radiotherapy (60.0 grays) and concomitant with anlotinib (12 mg once daily, 2 weeks on/1 week off), followed by six cycles of anlotinib maintenance. The primary end point was overall survival (OS). Secondary end points were progression‐free survival (PFS), OS rates at 12 and 24 months, PFS rates at 6 and 12 months, and safety. Results: Between October 12, 2020, and August 1, 2022, 32 patients were enrolled and received protocol therapy, and all were evaluable for efficacy and safety analyses. At a median follow‐up of 18.6 months (range, 8.3–50.3 months), the median OS was 19.1 months (95% confidence interval, 14.4–22.4 months), with 12‐month and 24‐month OS rates of 90.6% and 30.0%, respectively. The median OS did not reach the prespecified threshold of 20.1 months. The median PFS was 11.1 months (95% confidence interval, 9.6–12.9 months), with 6‐month and 12‐month PFS rates of 96.9% and 37.5%, respectively. Four patients (12.5%) experienced grade 3 or worse treatment‐related adverse events, two of which (6.3%) were serious. No treatment‐related deaths occurred. Conclusions: Postoperative anlotinib plus radiotherapy demonstrated clinically meaningful activity with a manageable safety profile in patients with unmethylated MGMT glioblastoma (Chinese Clinical Trials Registry identifier: ChiCTR2000040116).Keywords
Funding Information
- National Natural Science Foundation of China (82330085)
This publication has 30 references indexed in Scilit:
- Radiotherapy opens the blood–brain barrier and synergizes with anlotinib in treating glioblastomaRadiotherapy and Oncology, 2023
- Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)The Oncologist, 2021
- Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trialCancer Medicine, 2021
- Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent GlioblastomaThe Oncologist, 2020
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2018
- Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1Gene, 2018
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With GlioblastomaJAMA, 2017
- Vascular Mimicry: A Novel Neovascularization Mechanism Driving Anti-Angiogenic Therapy (AAT) Resistance in GlioblastomaTranslational Oncology, 2017
- Antiangiogenic therapy for high-grade gliomaCochrane Database of Systematic Reviews, 2014
- Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in GlioblastomaCancer Cell, 2011